| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Additional conditions recognized in this trial | ||||
| Gastroesophageal Reflux | |||||
| 2 | More general conditions related to this trial | ||||
| Deglutition Disorders | |||||
| Digestive System Diseases | |||||
| Esophageal Diseases | |||||
| Esophageal Motility Disorders | |||||
| Gastrointestinal Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| esomeprazole | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Aluminum Hydroxide | |||||
| Magnesium trisilicate | |||||
| Omeprazole | |||||
| 5 | More general drug interventions related to this trial | ||||
| Adjuvants, Immunologic | |||||
| Antacids | |||||
| Anti-Ulcer Agents | |||||
| Enzyme Inhibitors | |||||
| Gastrointestinal Agents | |||||
| Immunologic Factors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| AstraZeneca | |||||
|
